DURECT CORP: ASEN R SCOTT buys 5917 shares at $1.92 on 2025-08-22.

DURECT Corporation (DRRX) recently disclosed that a 10% owner, ASEN R Scott, acquired 5,917 shares at a price of $1.92 per share on August 22, 2025.

DURECT Corporation (DRRX) has experienced a significant insider buying activity recently. On August 22, 2025, ASEN R Scott, a 10% owner of the company, acquired 5,917 shares at a price of $1.92 per share. This purchase, as disclosed in a recent SEC filing [2], suggests a positive outlook on the part of the insider regarding the company's prospects.

The acquisition comes amidst Bausch Health's ongoing tender offer to acquire DURECT Corporation. Bausch Health, a global diversified pharmaceutical company, has extended its tender offer deadline to September 10, 2025, at 5:00 p.m. New York City time [1]. The tender offer values DURECT at $1.75 per share, with an upfront consideration of approximately $63 million at closing, and potential milestone payments of up to $350 million based on net sales achievements of larsucosterol [1].

The insider buying activity can be seen as a vote of confidence in DURECT's lead drug candidate, larsucosterol, which is in clinical development for the potential treatment of acute organ injury. The drug candidate has been granted a Fast Track and Breakthrough Therapy designation by the FDA [1].

While the insider's purchase may indicate optimism, investors should carefully consider the broader context, including the regulatory environment, competitive landscape, and the company's financial performance. The acquisition by ASEN R Scott also underscores the importance of insider trading policies and the potential influence of insider information on shareholder decisions.

References:
[1] https://www.stocktitan.net/news/BHC/bausch-health-announces-extension-of-durect-corporation-tender-offer-wtv9xzc9s84v.html
[2] https://www.marketscreener.com/news/durect-insider-bought-shares-worth-386-666-according-to-a-recent-sec-filing-ce7c50dade8af323